Nuveen’s Nektar Therapeutics NKTR Stock Holding History

Nuveen’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,747	Closed	-$4K	–	3236
2019 Q4	$4K	Buy	+13,747	New	+$3.99M	﹤0.01%	3210

Other funds holding NKTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's NKTR Position: Q2 2025 in Review

Nuveen sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 21,781 shares — an estimated $222K sold.

Nuveen first reported a position in NKTR in Q3 2013 and held it in 32 quarters. The position peaked at $33.3M in Q2 2019. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

Nuveen reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
Nuveen sold 21,781 Nektar Therapeutics shares in Q2 2025, an estimated $222K.
Nuveen first reported a position in Nektar Therapeutics in Q3 2013 and held it in 32 quarters.
Nuveen's Nektar Therapeutics position peaked at $33.3M in Q2 2019.
109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.